Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock units (RSUs) to a new non-executive employee. The Compensation Committee approved an award of 750 RSUs on June 2, 2025, under the company's 2024 Inducement Plan. The RSUs will vest over four years in equal annual installments, contingent on continued employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for equity awards to new employees as employment inducement. The 2024 Inducement Plan is specifically designed for granting equity awards to individuals who were not previously Praxis employees.
Praxis Precision Medicines (NASDAQ: PRAX), una societ脿 biofarmaceutica in fase clinica focalizzata sui disturbi del sistema nervoso centrale, ha assegnato unit脿 azionarie vincolate (RSU) a un nuovo dipendente non esecutivo. Il Comitato per la Remunerazione ha approvato il conferimento di 750 RSU il 2 giugno 2025, nell'ambito del Piano di Incentivazione 2024 dell'azienda. Le RSU matureranno in quattro anni con rate annuali uguali, subordinatamente alla permanenza in azienda. Questa assegnazione 猫 stata effettuata in conformit脿 alla Regola 5635(c)(4) del Nasdaq, che consente l'assegnazione di azioni a nuovi dipendenti come incentivo all'assunzione. Il Piano di Incentivazione 2024 猫 stato creato appositamente per concedere premi azionari a persone che non erano precedentemente dipendenti di Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en trastornos del sistema nervioso central, ha otorgado unidades restringidas de acciones (RSU) a un nuevo empleado no ejecutivo. El Comit茅 de Compensaci贸n aprob贸 una concesi贸n de 750 RSU el 2 de junio de 2025, bajo el Plan de Incentivos 2024 de la empresa. Las RSU se consolidar谩n durante cuatro a帽os en cuotas anuales iguales, condicionadas a la continuidad laboral. Esta concesi贸n se realiz贸 conforme a la Norma 5635(c)(4) de Nasdaq, que permite otorgar acciones a nuevos empleados como incentivo de contrataci贸n. El Plan de Incentivos 2024 est谩 dise帽ado espec铆ficamente para otorgar premios en acciones a personas que no eran empleados previos de Praxis.
Praxis Precision Medicines (NASDAQ : PRAX), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les troubles du syst猫me nerveux central, a accord茅 des unit茅s d鈥檃ctions restreintes (RSU) 脿 un nouvel employ茅 non cadre. Le comit茅 de r茅mun茅ration a approuv茅 une attribution de 750 RSU le 2 juin 2025, dans le cadre du Plan d鈥橧ncitation 2024 de la soci茅t茅. Les RSU seront acquises sur quatre ans par versements annuels 茅gaux, sous r茅serve de la poursuite de l鈥檈mploi. Cette attribution a 茅t茅 effectu茅e conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq, qui autorise les attributions d鈥檃ctions aux nouveaux employ茅s en tant qu鈥檌ncitation 脿 l鈥檈mbauche. Le Plan d鈥橧ncitation 2024 est sp茅cialement con莽u pour attribuer des actions 脿 des personnes qui n鈥櫭﹖aient pas auparavant employ茅es par Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Erkrankungen des zentralen Nervensystems, hat einem neuen nicht gesch盲ftsf眉hrenden Mitarbeiter Restricted Stock Units (RSUs) gew盲hrt. Der Verg眉tungsausschuss genehmigte am 2. Juni 2025 die Zuteilung von 750 RSUs im Rahmen des Inducement-Plans 2024 des Unternehmens. Die RSUs werden 眉ber vier Jahre in gleichen j盲hrlichen Raten unverfallbar, vorbehaltlich der fortgesetzten Besch盲ftigung. Diese Zuteilung erfolgte gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4), die Aktienzuteilungen an neue Mitarbeiter als Anreiz bei der Einstellung erlaubt. Der Inducement-Plan 2024 wurde speziell f眉r die Gew盲hrung von Aktienpr盲mien an Personen entwickelt, die zuvor keine Mitarbeiter von Praxis waren.
Positive
None.
Negative
None.
BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 2, 2025, the Compensation Committee of Praxis鈥� Board of Directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit award was granted as inducement material to the employee鈥檚 entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals鈥� entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee鈥檚 continued employment with Praxis on each vesting date.
About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽聽and follow us on聽,听听补苍诲听.
Contacts:
Investor Contact:
Praxis Precision Medicines
[email protected]聽
857-702-9452
Media Contact:
Dan Ferry
Life Science Advisors
[email protected]聽
617-430-7576
FAQ
What is the size of the RSU grant announced by Praxis Precision Medicines (PRAX)?
The RSU grant consists of 750 shares of common stock awarded to one new non-executive employee.
How will the PRAX restricted stock units vest?
The RSUs will vest in four equal annual installments, subject to the employee's continued employment with Praxis on each vesting date.
What is the purpose of Praxis Precision Medicines' 2024 Inducement Plan?
The 2024 Inducement Plan is used exclusively for granting equity awards to new Praxis employees as an inducement for joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
What type of company is Praxis Precision Medicines (PRAX)?
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
